Capricor Surges as 24-Month Deramiocel Data Show Durable Benefit in Duchenne
CAPR has more than doubled off its 52-week low of $2.96.
Summary
Capricor shares jumped in late trading after new 24-month data on deramiocel were presented in a late-breaking poster at the 31st Annual Congress of the World Muscle Society in Hiroshima, Japan. In the open-label extension, placebo crossover patients' upper limb decline slowed 76% in their first year on deramiocel, with a least-squares mean change of −0.49 in Year 2 versus −2.05 in Year 1, while the early-start deramiocel arm showed changes of −0.89 and −0.95, respectively. Both groups declined slower than natural history at 24 months, with observed changes of −3.76 and −3.42 versus predicted changes of −5.35 and −5.88. The analyses include a delayed-start comparison and natural history benchmark, with 82 of 106 HOPE-3 patients reaching 24 months. The data are part of the BLA amendment already under FDA review, with a PDUFA date of November 22. This follows the FDA advisory committee's 9-3 negative vote on cardiomyopathy effectiveness in July, but the new longer-term upper-limb data may strengthen the overall benefit-risk case. An oral presentation by Craig McDonald on October 3 will provide further detail on skeletal-muscle and cardiac effects.
Updated with a GlobeNewswire report · What changed
Updates
· GlobeNewswire — Placebo crossover patients' upper limb decline slowed 76% in their first year on deramiocel; both groups declined slower than natural history at 24 months.
- Upper Limb Decline — Placebo arm Year 1 LS mean change on placebo was −2.05 (n=52) and Year 2 on Deramiocel was −0.49 (n=49), a difference of 1.56 (95% CI: 0.47 to 2.64). Deramiocel arm Year 1 LS mean change was −0.95 (n=54) and Year 2 was −0.89 (n=49), a difference of 0.05 (95% CI: −1.03 to 1.14).
- Natural History Comparison
- Placebo arm (12 months on Deramiocel) observed Month 24 change was −3.76.
- Placebo arm (12 months on Deramiocel) predicted by natural history Month 24 change was −5.35.
- Deramiocel arm (24 months on Deramiocel) observed Month 24 change was −3.42.
- Deramiocel arm (24 months on Deramiocel) predicted by natural history Month 24 change was −5.88.
- The natural history model used was Michaëls 2025 and Niks 2026.
- In its untreated year, the Placebo arm tracked the model (−2.7 observed vs −2.9 predicted at Month 12).
- The natural history comparison was descriptive only; no matching or statistical testing.
- Slower decline in patients on Deramiocel was triggered by starting treatment, not passage of time.
- Natural history model (Michaëls 2025; Niks 2026) predicts each patient’s decline from baseline score, age and ambulatory status.
- Placebo arm's untreated year tracked a published non-ambulant cohort (about −2.7 points per year; Coratti 2025).
- Trial Design
- 98 patients entered the open-label extension (49 per arm).
- Patients assessed at Month 24 were 42 in placebo arm and 40 in Deramiocel arm.
- No alpha was allocated to these open-label analyses, and the extension was not powered for Month 24 comparisons.
- Least-squares mean change from a mixed model for repeated measures, adjusted for starting score, cohort, site and slow-progressor status.
- The BLA amendment included extensive sensitivity and robustness analyses.
- Deramiocel was administered intravenously every three months over a 12-month treatment period in the randomized phase.
- Least-squares mean change from a mixed model for repeated measures, with each year measured from its own starting point (Day 0 or Month 12) and adjusted for starting score, cohort, site and slow-progressor status.
- HOPE-3 is a Phase 3, randomized, double-blind, placebo-controlled trial.
- Upper limb function is measured by PUL 2.0 Total Score.
- Presentation — The 24-month data were presented in a late-breaking poster at the 31st Annual Congress of the World Muscle Society in Hiroshima, Japan.
All 27 details
- Placebo arm (delayed start) Year 1 LS mean change on placebo was −2.05 (n=52).
- Placebo arm (delayed start) Year 2 LS mean change on Deramiocel was −0.49 (n=49).
- Difference in decline rate for placebo arm, Year 2 vs Year 1, was 1.56 (95% CI: 0.47 to 2.64).
- Deramiocel arm (early start) Year 1 LS mean change on Deramiocel was −0.95 (n=54).
- Deramiocel arm (early start) Year 2 LS mean change on Deramiocel was −0.89 (n=49).
- Difference in decline rate for Deramiocel arm, Year 2 vs Year 1, was 0.05 (95% CI: −1.03 to 1.14).
- Placebo arm (12 months on Deramiocel) observed Month 24 change was −3.76.
- Placebo arm (12 months on Deramiocel) predicted by natural history Month 24 change was −5.35.
- Deramiocel arm (24 months on Deramiocel) observed Month 24 change was −3.42.
- Deramiocel arm (24 months on Deramiocel) predicted by natural history Month 24 change was −5.88.
- 98 patients entered the open-label extension (49 per arm).
- Patients assessed at Month 24 were 42 in placebo arm and 40 in Deramiocel arm.
- The 24-month data were presented in a late-breaking poster presentation at the 31st Annual Congress of the World Muscle Society in Hiroshima, Japan.
- No alpha was allocated to these open-label analyses, and the extension was not powered for Month 24 comparisons.
- Least-squares mean change from a mixed model for repeated measures, adjusted for starting score, cohort, site and slow-progressor status.
- The natural history model used was Michaëls 2025 and Niks 2026.
- In its untreated year, the Placebo arm tracked the model (−2.7 observed vs −2.9 predicted at Month 12).
- The natural history comparison was descriptive only; no matching or statistical testing.
- Slower decline in patients on Deramiocel was triggered by starting treatment, not passage of time.
- The BLA amendment included extensive sensitivity and robustness analyses.
- Deramiocel was administered intravenously every three months over a 12-month treatment period in the randomized phase.
- Least-squares mean change from a mixed model for repeated measures, with each year measured from its own starting point (Day 0 or Month 12) and adjusted for starting score, cohort, site and slow-progressor status.
- Natural history model (Michaëls 2025; Niks 2026) predicts each patient’s decline from baseline score, age and ambulatory status.
- Placebo arm's untreated year tracked a published non-ambulant cohort (about −2.7 points per year; Coratti 2025).
- HOPE-3 is a Phase 3, randomized, double-blind, placebo-controlled trial.
- Upper limb function is measured by PUL 2.0 Total Score.
- Deramiocel is also known as CAP-1002.
At the time of this announcement, CAPR was trading at $10.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $498.3M. The 52-week trading range was $2.96 to $40.37. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Seeking Alpha.